Comparison Between Pioglitazone and SES With type2 DM

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Drug-eluting stents have been shown to decrease restenosis, but were associated with an increased rate of death, as compared with bare-metal stents. Recently, thiazolidinediones effectively reduced restenosis and the risk of repeat target vessel revascularization. We conducted a study to compare the performance of a drug-eluting stent with that of a bare-metal stent with pioglitazone in patients with type 2 diabetic mellitus.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Showa University
• Treatments: Pioglitazone; Sirolimus

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes mellitus who had received coronary stenting were eligible for the study.

Exclusion Criteria:

• spastic angina pectoris

• congestive heart failure

• hepatic dysfunction

• chronic renal disease

• recent stroke

• impaired glucose tolerance

• insulin dependent diabetes mellitus

• familial hypercholesterolemia

• thyroid dysfunction

• adrenal dysfunction

• an intolerance of aspirin, ticlopidine, heparin, pioglitazone, stainless steel, or contrast material.